Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
Antitumor agent. It is a non-steroidal aromatase inhibitor, an enzyme that involves the synthesis of estrogens in postmenopausal women. Aromatase promotes the conversion of androgens synthesized in the adrenal glands (primarily androstenedione and testosterone), to estrone and estradiol. The inhibition of aromatase activity is realized by competitive binding to the subunit of this enzyme - heme cytochrome P450, which leads to a decrease in the biosynthesis of estrogens in all tissues, incl. in the tissues of estrogen-dependent tumors.
INDICATIONS
Treatment of malignant breast tumors in women in the period of natural or artificially induced menopause after treatment with antiestrogen drugs.
DOSING MODE
The dose is 2.5 mg 1 time / day daily. Treatment continues during the period of progression of the disease.
SIDE EFFECT
Possible: headache, nausea, peripheral edema, general weakness, hot flashes, thinning of the hair, skin rash, vomiting, dyspepsia, weight gain, musculoskeletal pain, anorexia, vaginal bleeding, leukorrhea, constipation, dizziness, increased appetite, increased sweating .
Rarely: shortness of breath, thrombophlebitis, spotting from the vagina.
CONTRAINDICATIONS
Endocrine status, characteristic of the premenopausal period; pregnancy, lactation, hypersensitivity to letrozole.
PREGNANCY AND LACTATION
Contraindicated in pregnancy, during lactation.
APPLICATION FOR FUNCTIONS OF THE LIVER
In patients with SC less than 10 ml / min, the safety of letrozole has not been studied, therefore, when it is necessary to use it in such cases, the ratio between the expected therapeutic effect and the possible risk of treatment should be carefully weighed.
SPECIAL INSTRUCTIONS
In patients with SC less than 10 ml / min, the safety of letrozole has not been studied, therefore, when it is necessary to use it in such cases, the ratio between the expected therapeutic effect and the possible risk of treatment should be carefully weighed.
Under the influence of letrozole, the ability to concentrate attention and the speed of psychomotor reactions can be reduced, therefore it is recommended to avoid driving vehicles and other potentially dangerous activities during the treatment period.
